/

Mersana Therapeutics, Inc.

MRSN US

MRSN USMersana Therapeutics, Inc.

United States Composite

3.53

USD

+0.03

(+0.71%)

-1.48EPS Dil.

-2.39P/E

425.51MMarket Cap

Mersana Therapeutics, Inc.

MRSN

(United States Composite)

Recent

price

3.53

P/E

ratio

-2.39

div

yld

- -

ROIC.AI

Legends:

Stock price

0.50

Beta (1.0 Market)

% total return 05/08

Stock

S&P500

YTD

-60.38

- -

-80.93

- -

-47.50

- -

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

- -

0.59

1.44

1.46

0.46

0.97

0.01

0.00

0.28

0.32

- -

-0.94

-0.78

-3.22

-2.79

-0.65

-1.43

-2.41

-2.18

-1.48

- -

-0.59

1.74

-3.64

-2.46

-1.57

-1.22

-1.99

-0.55

-1.47

- -

-2.60

-2.61

-4.30

-7.07

-4.24

-4.07

-6.11

-6.23

-6.85

- -

-2.44

-2.46

3.07

0.38

1.73

3.31

1.65

0.88

0.31

- -

116

- -

-157.75

-54.91

-225.80

-619.74

-71.69

-10,641.30

-392,693.02

-766.59

-463.86

- -

-16

-14

-39

-64

-28

-88

-170

-204

-172

- -

-158.59

-54.43

-220.62

-606.54

-66.97

-10,633.45

-395,488.37

-768.26

-465.80

- -

229

141

228

150

- -

-43

-56

228

122

- -

Capital Structure

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

ST Debt

LT Borrowings

LT Finance Leases

Preferred Equity and Hybrid Capital

- -

Shares Outstanding

120

121

Market Capitalization

396

153

280

Working Capital

FRC

•

in mil. unless spec.

Jun'23

Sep'23

Dec'23

Total Current Assets

297

250

214

Cash, Cash Equivalents & STI

287

241

209

Accounts Receivable, Net

- -

Inventories

- -

Total Current Liabilities

Payables & Accruals

ST Debt

Deferred Revenue

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years

5 years

1 year

Sales/Revenue/Turnover

0.00%

37.04%

Net Income, GAAP

-NaN%

-51.11%

15.69%

Free Cash Flow

-NaN%

-56.66%

-228.85%

Total Cash Common Dividend

- -

Total Equity

-NaN%

165.62%

-59.78%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

2021

2022

2023

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

2021

-0.50

-0.59

-0.63

-0.68

-2.41

2022

-0.59

-0.55

-0.61

-0.44

-2.18

2023

-0.52

-0.47

-0.35

-0.16

-1.48

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

2021

- -

2022

- -

2023

- -

Business: Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Company News

GuruFocus.com
5 days ago
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
5 days ago
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance
5 days ago
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GuruFocus.com
6 days ago
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
Yahoo Finance
6 days ago
Mersana Therapeutics to Host First Quarter 2024 Conference Call on May 9, 2024
Zacks
6 days ago
Moderna (MRNA) Reports Q1 Loss, Tops Revenue Estimates
Zacks
a month ago
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Yahoo
a month ago
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
Yahoo Finance
a month ago
Strength Seen in Curis (CRIS): Can Its 19.5% Jump Turn into More Strength?
GuruFocus.com
a month ago
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo Finance
a month ago
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Yahoo
a month ago
Mersana Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

- -

2015

2016

2017

2018

2019

2020

2021

2022

2023

TTM

FRC

- -

0.59

1.44

1.46

0.46

0.97

0.01

0.00

0.28

0.32

- -

-0.94

-0.78

-3.22

-2.79

-0.65

-1.43

-2.41

-2.18

-1.48

- -

-0.59

1.74

-3.64

-2.46

-1.57

-1.22

-1.99

-0.55

-1.47

- -

-2.60

-2.61

-4.30

-7.07

-4.24

-4.07

-6.11

-6.23

-6.85

- -

-2.44

-2.46

3.07

0.38

1.73

3.31

1.65

0.88

0.31

- -

116

- -

-157.75

-54.91

-225.80

-619.74

-71.69

-10,641.30

-392,693.02

-766.59

-463.86

- -

-16

-14

-39

-64

-28

-88

-170

-204

-172

- -

-158.59

-54.43

-220.62

-606.54

-66.97

-10,633.45

-395,488.37

-768.26

-465.80

- -

229

141

228

150

- -

-43

-56

228

122

- -